Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Japanese encephalitis vaccine, live
- Development stage
- Unknown
- Lead developer
- Chengdu Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The drug designation 'japanese encephalitis vaccine, live-Liaoning Chengda Biotechnology CO., LTD-Japanese encephalitis' refers to the live attenuated Japanese encephalitis vaccine (specifically the SA14-14-2 strain) as utilized in clinical trials sponsored by Liaoning Chengda Biotechnology Co., Ltd. While the input name associates the live vaccine with Liaoning Chengda, that company primarily manufactures an inactivated Vero cell-derived vaccine (JEVAC). The live attenuated vaccine is produced by the Chengdu Institute of Biological Products and is based on the SA14-14-2 strain of the Japanese encephalitis virus, which has been attenuated through serial passage in primary hamster kidney cells. It works by inducing a robust and long-lasting immune response, including the production of neutralizing antibodies against the virus's envelope protein. It is widely used in China and other endemic regions to provide protection against Japanese encephalitis, a mosquito-borne viral infection that can cause severe neurological disease.
- Brand names
- CD.JEV
- Other names
- Live attenuated Japanese encephalitis vaccineSA14-14-2 vaccineSA-14-14-2 vaccineSA 14-14-2 vaccinejapanese encephalitis vaccine, live-Liaoning Chengda Biotechnology CO., LTD-Japanese encephalitis
Beyond the preview
Go deeper on Japanese encephalitis vaccine, live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Japanese encephalitis vaccine, live.